Unique Offerings Accelerate Production of CAR-TCR Therapies
From discovery to BLA, accelerate your journey from research to market.
WuXi Advanced Therapies has a proven track record in assisting cell therapy developers go from IND to BLA. We've accelerated production globally, with 40+ INDs/BLAs approved, 3,000+ GMP lots manufactured, and testing for 27+ commercial release programs.
Please share your contact information. We'll email you links to the downloads listed below.
Submit your details
Gain access to the following downloads
XOFLX™ Stable Technology: A Simplified High-Yielding LVV Manufacturing System that Lowers Costs & Improves Process Consistency
Presentation
This download was presented by Dr. Qian Liu, at the CAR-TCR Summit in London on February 28th, 2024, in London. Her presentation describes the innovative XOFLX™ (pronounced So-flex) stable technology which delivers large quantities of high-quality lentiviral vectors (LVV) with demonstrated safety and efficacy.
XOFLX™ Lenti Platform: Stable Lentiviral Vector Production Cell Lines Yield LVV Titres Comparable to the Four-Plasmid Process
Poster
This poster illustrates how XOFLX™ packaging and producer cell lines reduce/ eliminate plasmid transfection dependency, reducing manufacturing cost and process variability.
Please complete the form below to receive the downloads listed via email
"*" indicates required fields